Table 2.
List of CAR-NK cells in clinical trials.
| Clinical Trial Identifier |
Trial Name | Antigen Target |
Disease Indication |
NK Cell Source |
Trial Status |
Year Trial Started |
Armor |
|---|---|---|---|---|---|---|---|
| NCT03056339 | Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies | CD19 | Stem Cell Transplant Patients with Relapsed and/or Refractory B-Cell Lymphoma or Leukemia | Cord Blood | Active, not recruiting | 2017 | iCasp9 and IL-15 |
| NCT03692663 | Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer | PSMA | Metastatic Castration-Resistant Prostate Cancer | Unknown | Recruiting | 2018 | N/A |
| NCT04623944 | NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS | NKG2D Ligands | Relapsed or Refractory Acute Myeloid Leukemia or Intermediate, High and Very High Risk Relapsed or Refractory MDS | Either Haplo-Matched Related Donor Derived or Unrelated Off-the-Shelf Donor Derived | Recruiting | 2020 | Membrane-Bound IL-15 |
| NCT04887012 | Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL | CD19 | B-cell Non-Hodgkin's lymphoma | HLA haploidentical | Recruiting | 2021 | N/A |
| NCT05008575 | Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | CD33 | Acute Myeloid Leukemia | Unknown | Recruiting | 2021 | N/A |
| NCT05008536 | Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma | BCMA | Multiple Myeloma, Refractory | Umbilical and Cord Blood | Recruiting | 2021 | N/A |
| NCT04847466 | Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer | PD-L1 | Gastroesophageal Junction Cancers Advanced HNSCC | NK-92 | Recruiting | 2021 | N/A |
| NCT04796675 | Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies | CD19 | Relapsed or Refractory Hematological Malignancies | Cord Blood | Recruiting | 2021 | N/A |
| NCT05020678 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | CD19 | Relapsed or Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or B cell Acute Lymphoblastic Leukemia | Either Haplo-Matched Related Donor Derived or Unrelated Off-the-Shelf Donor Derived | Recruiting | 2021 | Membrane-Bound IL-15 |
| NCT05247957 | NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia | NKG2D | Recurrent Refractory Acute Myeloid Leukemia | Umbilical Cord | Recruiting | 2022 | N/A |
| NCT05410717 | CLDN6-CAR-NK Cell Therapy for Advanced Solid Tumors | Claudin6 | Advanced Solid Tumors | Autologous PBMC | Recruiting | 2022 | IL7 + CCL19 or scFvs Against PD1/CTLA4/Lag3 |
| NCT05213195 | NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer | NKG2D | Refractory Metastatic Colorectal Cancer | Unknown | Recruiting | 2022 | N/A |
| NCT05215015 | Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia | CD33/CLL1 | Acute Myeloid Leukemia | Unknown | Recruiting | 2022 | N/A |
| NCT05194709 | Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors | 5T4 | Advanced Solid Tumors | Unknown | Recruiting | 2022 | N/A |
| NCT05410041 | Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies | CD19 | Recurrent or Refractory CD19-Positive B-Cell Malignant Tumors | Unknown | Recruiting | 2022 | N/A |
| NCT05379647 | Natural Killer (NK) Cell Therapy for B-Cell Malignancies | CD19 | Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Relapsed or Refractory B-cell Lymphoma | Unknown | Recruiting | 2022 | N/A |
| NCT05182073 | FT576 in Subjects With Multiple Myeloma | BCMA | Multiple Myeloma | iPSC | Recruiting | 2022 | Modified CD16, IL-15 Receptor Fusion, Elimination of CD38 |